|
|
|
| Early therapeutic response of rAd/p53 in human colon cancer model using MR-DWI |
| XIE Qi1, ZHANG Ding-xuan1, LIANG Bi-ling2, CHEN Ming-wang3, ZHANG Jing3, WU Yan-heng4 |
| 1. Imaging Department, Nansha Center Hospital, Guangzhou Municipal First People’s Hospital,Guangzhou Medical College, Guangzhou 510240, China;2. Department of Radiology, the Second Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510120, China;3. Guangzhou Municipal First People’s Hospital, Guangzhou Medical College, Guangzhou 510180, China;4. Department of Imaging, the First Clinical Medical College, Jinan University, Guangzhou 510635, China |
|
|
|
|
Abstract Objective: To study the early response of rAd/p53 in nude mice bearing human colon cancer model of SW480 using MR-DWI. Methods: The tumor pieces of human colon cancer SW480 were injected subcutaneously into 52 nude mice. These mice were divided randomly into two groups that is the control group and the therapeutic group. rAd/p53 was injected into the tumor of the mice in the therapeutic group, while saline was injected into the tumor of the mice in the control group. At 24 h, 48 h, 72 h, 120 h and 168 h after treatment, MR-DWI was performed with 1.5T MR system for five mice at each time point of each group. Then the mice were sacrificed and the tumor in which were removed. P53 expression(western blot) and apoptosis of tumor(TUNNEL) were assessed. Results: ADC values of tumors in each time point after rAd/p53 injection were higher than those of the control groups. EADC values after rAd/p53 injection were lower than those of the control groups. p53 expression and apoptosis of the tumor in the therapeutic group were higher than that of the control groups. ADC value showed positive correlations with the extent of apoptosis of tumor cells and showed positive correlation with p53 expression. EADC value showed negative correlations with the apoptotic extent of tumor cells and negative correlation with p53 expression. Conclusions: ADC value and EADC value change significantly at 24 h after treatment. They can be used as biomarker in evaluation of early response of rAd/p53 in the treatment of tumor.
|
|
Received: 11 July 2011
|
|
|
|
|
|
|
|
|
2012, Vol. 23 
